



ShareSoc

UK Individual Shareholders Society

20 Wenlock Road
London - N1 7GU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.



GENI – Genincode

8.50p 0.25 +2.97%

 EMS: 5k

Market Cap

Enterprise Value

Revenue

Position in Market

£7.90m

£3.02m

£1.72m

1393rd / 1,701

Quality

Value

Momentum

StockRank™

21

8

8

4

Healthcare · Highly Speculative · Micro Cap · Sucker Stock



Momentum

Relative Strength (%)	
1m	-27.5% ●
3m	-29.1% ●
6m	-47.8% ●
1y	-56.6% ●
Volume Change (%)	
10d / 3m	-62.4% ●
Price vs... (%)	
52w High	-68.3% ●
50d MA	-25.5% ●
200d MA	-42.7% ●

Growth & Value

12m Forecast Rolling		Industry	Market
PE Ratio (f)	n/a		
PEG Ratio (f)	n/a		
EPS Growth (f)	n/a		
Dividend Yield (f)	0.00%		
Valuation (ttm)		Industry	Market
Price to Book Value	1.66		
Price to Tang. Book	1.77		
Price to Free Cashflow	n/a		
Price to Sales	4.61		
EV to EBITDA	n/a		

Shareholder Activity

Buy / Hold / Sell	
Institutions	
Directors	
Community	Insufficient data available

Screens Passed: 0 Long 1 Short

GENI qualifies for **Altman Z-Score Screen** (Short Selling)

[View Screen](#) [View Checklists](#)

Quality

		Industry	Market
Return on Capital	-116.6%		
Return on Equity	-84.2%		
Operating Margin	-415.56%		

Financial Summary

Year End 31st Dec		2017	2018	2019	2020	2021	2022	TTM	2023E	2024E	CAGR / Avg
Total Revenue	£m				0.961	1.15	1.43	1.72	2.40	5.90	22.0%
Operating Profit	£m				-1.05	-4.15	-5.90	-7.13			
Net Profit	£m				-1.17	-4.14	-5.56	-6.73	-6.89	-7.73	
EPS Reported	p	0.000	0.000	0.000	-1.22	-4.32	-5.80	-7.03			
EPS Normalised	p	0.000	0.000	0.000	-1.22	-3.91	-5.80	-7.03	-7.13	-8.06	
EPS Growth	%										
PE Ratio	x										
PEG											
Profitability											
Operating Margin	%				-109	-359	-413	-416			-294%
ROA	%				-96.3	-47.0		-65.9			
ROCE	%				-56.5	-28.8	-61.3	-117			-48.9%
ROE	%				-125	-53.2	-51.4	-84.2			-76.7%
Cashflow											
Op. Cashflow ps	p	0.000	0.000	0.000	-1.08	-3.16	-4.30	-6.99			
Capex ps	p	0.000	0.000	0.000	0.071	0.151	0.886	0.757			253%
Free Cashflow ps	p	0.000	0.000	0.000	-1.15	-3.31	-5.19	-7.75			
Dividends											
Ex-date: 17 Oct / Paid: 17 Oct											
Dividend ps	p	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
Dividend Growth	%										
Dividend Yield	%							0.000	0.000	0.000	
Dividend Cover	x										
Balance Sheet											
Cash etc	£m				2.00	14.6	9.75	5.21			121%
Working Capital	£m	0.000	0.000	0.000	1.71	14.1	8.31	4.96			121%

Health Trend (F-Score)

5/9

0 1 2 3 4 5 6 7 8 9

Bankruptcy Risk (Z1-Score)

-2.53

Distress Cautious Safe

Earnings Manipulation Risk (M-Score)

n/a

Other Ratios

Leverage (ttm)	Total	- Intang	+ Pension
Gross Gearing %	6.7	7.2	6.7
Net Gearing %	-102.56	-109.41	-102.6
Cash / Assets %	73.07		73.1
Liquidity (ttm)			
Curr. Ratio			5.92 ●
Quick Ratio			5.85 ●
Interest Cov.			100.00 ●
Efficiency (ttm)			
Asset Turnover			0.18
Recs Turnover			2.88
Stock Turnover			16.36

Year End 31st Dec		2017	2018	2019	2020	2021	2022	TTM	2023E	2024E	CAGR / Avg
Net Debt	£m	0.000	0.000	0.000	-2.00	-14.6	-9.39	-4.88			
Net Fixed Assets	£m	0.000	0.000	0.000	0.013	0.046	1.00	0.855			780%
Book Value	£m	0.000	0.000	0.000	1.86	13.7	7.90	4.76			106%
Average Shares	m				96	96	96	96			0%
Book Value ps	p	0.000	0.000	0.000	1.94	14.3	8.24	4.97			106%


FINANCIAL BRIEF: For the six months ended 30 June 2023, Genincode PLC revenues increased 43% to £950K. Net loss increased... [See more](#)

Recent History


Latest interim period vs. prior period	Industry	Market
Sales Growth	43.07%	
EPS Growth	n/a	
3yr Compound Annual Growth Rate	Industry	Market
Sales CAGR	n/a	
EPS CAGR	n/a	
DPS CAGR	n/a	

Graphical History


Revenue




Net Income




Normalised EPS



PE Ratio Range



Dividend Yield Range




Analyst Forecasts


Price Target: 101.00p (1,124.24% above Price)	31st Dec 2023			31st Dec 2024		
Est. Long Term Growth Rate:	Net Profit (£)	EPS (p)	DPS (p)	Net Profit (£)	EPS (p)	DPS (p)
Consensus Estimate	-6.89m	-7.1	0.0	-7.73m	-8.1	0.0
1m Change		0.0		-326.00k	-0.2	
3m Change		0.0		-326.00k	-0.2	

Analyst Consensus

3 brokers



EPS 2023 / 2024



Profile Summary

GENinCode Plc is a United Kingdom-based predictive genetics company. The Company is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo and Thrombo Incode Reproductive Health. Th... [Read more](#)

Directors

William Rhodes NEC

Matthew Walls CEO

Paul Foulger CFO

Huon Gray NID

Felix Frueh NID

Jordi Gilbarte COO

Sergio Olivero NID

Last Annual	Dec 31, 2022
Last Interim	Jun 30, 2023
Incorporated	Sep 6, 2018
Public Since	Jul 22, 2021
Ex-Dividend Date	Oct 17, 2023
Payment Date	Oct 17, 2023
No. of Employees	28
No. of Shareholders	n/a

Sector
Industry
Index

Exchange
Asset Category
Shares in Issue
Free Float
Eligible for

Healthcare
Healthcare Equipment & Supplies
FTSE AIM All Share Index, AIM Health Care Index

LSE AIM Market
Common Stock
95,816,866
42,114,638 (43.95%)

ISAs

SIPPs

Address
1 St. Peters Square, OXFORD,
OX4 4GP, United Kingdom


Web
<https://www.genincode.com/>

Phone
+441865955847

Auditors
Jeffreys Henry LLP

GENI Share Price Performance

Share Price	Volume	Bid - Ask	Low - High	Spread
8.50p	192	8.00p - 8.50p	0.00p - 0.00p	606bps
Day's Change	Avg Volume	Open - Close	Range (12m)	Beta
0.25 +2.97%	52,656	8.25p - 8.25p	6.50p - 26.00p	



Latest News for GENI

Thu, Oct 12, 2023

RCS - GENinCode PLC - ShareSoc investor presentation

Announcement

Sep 20, 2023

BRIEF-Genincode PLC H1 Revenue Rose 43 Percent To 950,000 Stg

News

Sep 20, 2023

GENinCode PLC - Half-year Report

Announcement

Sep 13, 2023

GENinCode PLC - Notice of Results

Announcement

Aug 30, 2023

GENinCode PLC - Presentation at European Society of Cardiology

Announcement

Upcoming Events for GENI

Thursday, October 19th 2023

Genincode PLC at ShareSoc and Walbrook PR Healthcare Companies Seminar

Similar to GENI

Compare

☐		BioSino Bio-technology and Science Neutral	29
☐		Huakang Biomedical Holdings Co Sucker Stock	14
☐		Ikonisys SA Sucker Stock	9
☐		Applied DNA Sciences Neutral	21
☐		BCAL Diagnostics Neutral	20
☐		Cambridge Nutritional Sciences Value Trap	21
☐		PZ Cormay SA Neutral	12
☐		Redsense Medical AB (publ) Momentum Trap	26

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2023 © Stockopedia 2023, Refinitiv, Share Data Services.

- **Important Information:** To use Stockopedia, you must accept our Terms of Use, Privacy and Disclaimer & FSG. All financial services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.
- This communication cannot substitute for professional investment advice or independent factual verification. Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.
- Information in this commentary is current as at date prepared unless otherwise stated. However, please bear in mind that investments can go up or down in value, and that past performance is not a reliable indicator of future performance. Stockopedia looks for stocks that meet certain pre-defined criteria and presents the results to help users perform their own research. For more Important Information please refer to the Disclaimer section in the Stockopedia website.
- This communication may contain general Financial product advice. It has been prepared without taking into account your personal circumstances, and you should therefore consider its appropriateness in light of your objectives, financial circumstances and needs before acting on it.
- Company data is derived from data provided by Refinitiv
- Each company on Stockopedia is evaluated on the basis of hundreds of fundamental and technical metrics that measure a company's Quality, Value, Growth, and Momentum.
- QVM StockRanks™:
 - This measure equally blends the Quality, Value and Momentum ranks into a core metric, the StockRank.
- QualityRank™:
 - The QualityRank is based on a composite of carefully selected company factors based on the latest academic research into understanding 'Quality'. The factors used are inspired by the writings of Warren Buffett, Joseph Piotroski, Edward Altman and Messod Beneish, as well as recent papers from Robert Novy-Marx of the University of Chicago and National Bureau of Economic Research.
 - Each company in the market is ranked from 1 to 100 for each of these Quality Factors and a composite score is calculated as a weighted average of all these values. The QualityRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- ValueRank™:
 - Our ValueRank is based on a composite of the following Value factors: Price to Book Value ; Price to Earnings ; Price to Free Cash Flow ; Dividend Yield % ; Price to Sales ; Earnings Yield %

- Consistent with the value investing philosophy, we use historic ratios for each of these metrics, rather than factoring in analyst forecasts. Each company in the market is ranked from 1 to 100 for each of these value ratios and a composite score is calculated as the weighted average of all valid values. The ValueRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- MomentumRank™:
 - The MomentumRank is based on a composite of the following Price and Estimate Momentum Factors.
 - Price Momentum Factors:
 - Proximity of current share price to the 52 week high ; 50 day vs 200 day moving averages ; 1 year Relative Strength of the share price vs the market ; 6 Month Relative Strength of the share price vs the market.
 - Earnings Momentum Factors:
 - EPS estimate upgrades within the last one month for next financial year ; EPS estimate upgrades within the last three months for this financial year ; EPS surprise percentage based on the latest reported financials ; Scaled earnings surprise based on the standard deviation of the original Consensus forecast ; Consensus broker recommendation upgrade over the last month
 - Each company in the market is ranked from 1 to 100 for each of these momentum ratios and a composite score is calculated as a weighted average of all valid values. The MomentumRank is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
 - When a company has no broker coverage we cannot calculate earnings momentum. As a result the Momentum Rank is calculated using price momentum factors alone.